SHANGHAI, China, Nov. 02, 2020 (GLOBE NEWSWIRE) — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products
that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the National Medical Products Administration (NMPA) of the People’s Republic of
China